Epigenome-wide DNA methylation regulates cardinal pathological features of psoriasis

Aditi Chandra, Swapan Senapati, Sudipta Roy, Gobinda Chatterjee, Raghunath ChatterjeeClinical 2018 · DOI

TL;DR

This study reveals that DNA methylation, an epigenetic mechanism, plays a crucial role in regulating the characteristic pathological features of psoriasis. By analyzing genome-wide methylation patterns in psoriatic skin, researchers identified specific methylation changes linked to key disease hallmarks, suggesting potential new therapeutic targets.

What Problem Does This Paper Address?

Psoriasis is a chronic inflammatory skin disease with complex origins, involving genetic, epigenetic, and environmental factors. While genetic predispositions are known, the exact mechanisms driving its characteristic histopathological features—such as increased skin cell proliferation, abnormal differentiation, and immune cell infiltration—remain incompletely understood. Epigenetic modifications, particularly DNA methylation, have been implicated, but their direct link to specific psoriasis features and their potential reversibility during treatment have not been thoroughly investigated. This paper aims to bridge this gap by exploring how genome-wide DNA methylation patterns correlate with and potentially regulate these cardinal pathological features of psoriasis.

Methods

The researchers employed a genome-wide DNA methylation profiling approach using the Illumina Infinium Human Methylation 450k BeadChip on paired psoriatic and adjacent normal skin tissues from 24 patients. Differentially methylated probes (DMPs) were identified using a stringent statistical cut-off (adjusted P value ≤ 0.05 and |Δβ| > 0.15). To validate their findings, they used bisulfite sequencing PCR (BSP) and quantitative methylation-specific PCR (qMSP) on an independent set of samples. Gene expression analysis was performed using qPCR to assess the downstream effects of promoter methylation. To further confirm the regulatory role of methylation, they cloned CpG-poor promoter regions into a luciferase reporter vector and tested their expression after enzymatic methylation. Finally, they correlated methylation patterns with specific histopathological features like Munro's microabscess, Kogoj's microabscess, rete peg elongation, and focal hypergranulosis.

Datasets

The study utilized paired psoriatic and adjacent normal skin biopsies from 39 patients. A discovery cohort of 24 paired samples was used for genome-wide profiling, and a validation cohort of 15 paired samples was used for validating specific DMPs and gene expression. Histopathological analysis was performed on these samples to assess specific disease features.

Key Insights and Ideas

  • DNA methylation is a key regulator of psoriasis pathology: The study provides strong evidence that DNA methylation isn't just associated with psoriasis but actively influences its characteristic features.
  • Specific methylation patterns link to distinct histopathological hallmarks: Researchers found unique methylation signatures associated with features like neutrophil infiltration (Munro's microabscess), rete peg elongation, and altered keratinocyte differentiation (focal hypergranulosis).
  • Epigenetic reversibility mirrors clinical remission: The observation that aberrant methylation can reverse to normal levels, similar to how histopathological features resolve during treatment, highlights the dynamic and potentially targetable nature of the disease.
  • CpG-poor promoters are sensitive to methylation changes: The study found that even promoters with few CpG sites can be epigenetically regulated, impacting gene expression and contributing to disease phenotypes.
  • Overlap with psoriasis susceptibility regions (PSORS): A significant portion of the identified DMPs overlapped with known genetic susceptibility loci for psoriasis, suggesting an interplay between genetic predisposition and epigenetic regulation.

Key Results

  • 4133 Differentially Methylated Probes (DMPs) identified: The genome-wide analysis revealed a substantial number of DMPs between psoriatic and normal skin tissues.
  • Hypermethylation is prevalent: Approximately 62% of the identified DMPs were hypermethylated in psoriatic tissues.
  • Enrichment in specific genomic regions: DMPs were predominantly found in introns and promoters, with a notable enrichment in psoriasis susceptibility regions (PSORS).
  • Inverse correlation between methylation and gene expression: For several key genes (e.g., SELENBP1, PTPN22, S100A9), increased promoter methylation was associated with decreased gene expression, and vice versa.
  • Functional links to histopathology: Gene ontology analysis linked differentially methylated promoters to processes like neutrophil chemotaxis (associated with Munro's microabscess) and immune system regulation.
  • Reporter assay confirms regulatory role: Luciferase reporter assays demonstrated that methylation of specific promoter regions could indeed abrogate gene expression.

Limitations and Future Work

The study acknowledges that using total skin biopsy samples, which contain a heterogeneous mix of cell types (epidermal, dermal, immune cells), can lead to averaged-out methylation signals and potentially miss subtle, cell-type-specific changes. While they controlled for this by comparing paired samples and using stringent statistical cut-offs, future work could benefit from single-cell methylation analysis to dissect cell-type-specific epigenetic landscapes in psoriasis. The authors also suggest that further validation and functional studies are needed to precisely identify the most clinically significant epigenetically regulated genes in psoriasis, which could serve as targets for novel therapeutic interventions. The identification of common DMPs across different histopathological features also presents an avenue for developing broad-acting therapeutic strategies.

Summary updated

Abstract

Our study, for the first time, indicated the possible involvement of DNA methylation in regulating the cardinal pathophysiological features in psoriasis. Common genes involved in regulation of these pathologies may be used to develop drugs for better clinical management of psoriasis.
BibTeX
@inproceedings{chandra2018epigenome,
  author = {Aditi Chandra and Swapan Senapati and Sudipta Roy and Gobinda Chatterjee and Raghunath Chatterjee},
  title = {{Epigenome-wide DNA methylation regulates cardinal pathological features of psoriasis}},
  booktitle = {Clinical},
  year = {2018},
  doi = {10.1186/s13148-018-0541-9},
}
Figure